Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor-Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002).
Hua X, Bi XW, Zhao JL, Shi YX, Lin Y, Wu ZY, Zhang YQ, Zhang LH, Zhang AQ, Huang H, Liu XM, Xu F, Guo Y, Xia W, Hong RX, Jiang KK, Xue C, An X, Zhong YY, Wang SS, Huang JJ, Yuan ZY.
Hua X, et al.
Clin Cancer Res. 2022 Feb 15;28(4):637-645. doi: 10.1158/1078-0432.CCR-21-3435.
Clin Cancer Res. 2022.
PMID: 34810217
Free PMC article.
Clinical Trial.